Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemia

C. F. LeMaistre; C. M. Meneghetti; A. B. Deisseroth; M. G. Rosenblum; J. M. Reuben; D. R. Parkinson; K. Parker; J. P. Shaw; T. Woodworth

doi:10.1016/0140-6736(91)92788-4

Therapeutic effects of genetically engineered toxin (DAB₄₈₆IL-2) in patient with chronic lymphocytic leukaemia

C. F. LeMaistre, C. M. Meneghetti, A. B. Deisseroth, M. G. Rosenblum, J. M. Reuben, D. R. Parkinson, K. Parker, J. P. Shaw, T. Woodworth

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Abstract

In DAB₄₈₆IL-2 the receptor-binding domain of native diphtheria toxin is replaced by human IL-2 sequences. This recombinant fusion protein is selectively cytotoxic for cells bearing high-affinity IL-2 receptors-eg, leukaemic cells. A patient with chronic lymphocytic leukaemia who did not respond to gamma interferon and conventional antileukaemic drugs has responded to DAB₄₈₆IL-2.

Original language	English (US)
Pages (from-to)	1124-1125
Number of pages	2
Journal	The Lancet
Volume	337
Issue number	8750
DOIs	https://doi.org/10.1016/0140-6736(91)92788-4
State	Published - May 11 1991

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/0140-6736(91)92788-4

Cite this

@article{c6acfaa458004b61b1e5bfcd20e46543,

title = "Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemia",

abstract = "In DAB486IL-2 the receptor-binding domain of native diphtheria toxin is replaced by human IL-2 sequences. This recombinant fusion protein is selectively cytotoxic for cells bearing high-affinity IL-2 receptors-eg, leukaemic cells. A patient with chronic lymphocytic leukaemia who did not respond to gamma interferon and conventional antileukaemic drugs has responded to DAB486IL-2.",

author = "LeMaistre, {C. F.} and Meneghetti, {C. M.} and Deisseroth, {A. B.} and Rosenblum, {M. G.} and Reuben, {J. M.} and Parkinson, {D. R.} and K. Parker and Shaw, {J. P.} and T. Woodworth",

year = "1991",

month = may,

day = "11",

doi = "10.1016/0140-6736(91)92788-4",

language = "English (US)",

volume = "337",

pages = "1124--1125",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "8750",

}

TY - JOUR

T1 - Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemia

AU - LeMaistre, C. F.

AU - Meneghetti, C. M.

AU - Deisseroth, A. B.

AU - Rosenblum, M. G.

AU - Reuben, J. M.

AU - Parkinson, D. R.

AU - Parker, K.

AU - Shaw, J. P.

AU - Woodworth, T.

PY - 1991/5/11

Y1 - 1991/5/11

N2 - In DAB486IL-2 the receptor-binding domain of native diphtheria toxin is replaced by human IL-2 sequences. This recombinant fusion protein is selectively cytotoxic for cells bearing high-affinity IL-2 receptors-eg, leukaemic cells. A patient with chronic lymphocytic leukaemia who did not respond to gamma interferon and conventional antileukaemic drugs has responded to DAB486IL-2.

AB - In DAB486IL-2 the receptor-binding domain of native diphtheria toxin is replaced by human IL-2 sequences. This recombinant fusion protein is selectively cytotoxic for cells bearing high-affinity IL-2 receptors-eg, leukaemic cells. A patient with chronic lymphocytic leukaemia who did not respond to gamma interferon and conventional antileukaemic drugs has responded to DAB486IL-2.

UR - http://www.scopus.com/inward/record.url?scp=0025853356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025853356&partnerID=8YFLogxK

U2 - 10.1016/0140-6736(91)92788-4

DO - 10.1016/0140-6736(91)92788-4

M3 - Article

C2 - 1674015

AN - SCOPUS:0025853356

SN - 0140-6736

VL - 337

SP - 1124

EP - 1125

JO - The Lancet

JF - The Lancet

IS - 8750

ER -

Therapeutic effects of genetically engineered toxin (DAB₄₈₆IL-2) in patient with chronic lymphocytic leukaemia

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this